Sign in or create an account to add this stock to your watchlist.
About TherapeuticsMD (NASDAQ:TXMD)
TherapeuticsMD, Inc. operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands. It markets its products primarily through a direct national sales force to health care providers in the OB/GYN market space. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TXMD
CUSIPN/A
Phone561-961-1900
Debt
Debt-to-Equity RatioN/A
Current Ratio7.61
Quick Ratio7.51
Price-To-Earnings
Trailing P/E Ratio-16.00
Forward P/E Ratio-15.26
P/E GrowthN/A
Sales & Book Value
Annual Sales$16.78 million
Price / Sales76.80
Cash FlowN/A
Price / CashN/A
Book Value$0.50 per share
Price / Book11.90
Profitability
EPS (Most Recent Fiscal Year)($0.37)
Net Income$-76,920,000.00
Net Margins-483.98%
Return on Equity-66.77%
Return on Assets-60.12%
Miscellaneous
Employees173
Outstanding Shares216,580,000
TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions
What is TherapeuticsMD's stock symbol?
TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."
How were TherapeuticsMD's earnings last quarter?
TherapeuticsMD Inc (NASDAQ:TXMD) announced its earnings results on Thursday, May, 3rd. The company reported ($0.11) EPS for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.01. The company earned $3.77 million during the quarter, compared to analysts' expectations of $4.18 million. TherapeuticsMD had a negative return on equity of 66.77% and a negative net margin of 483.98%. TherapeuticsMD's revenue for the quarter was down 5.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.11) EPS. View TherapeuticsMD's Earnings History.
What price target have analysts set for TXMD?
9 brokers have issued 12-month price objectives for TherapeuticsMD's shares. Their predictions range from $6.00 to $28.00. On average, they expect TherapeuticsMD's share price to reach $14.8571 in the next year. View Analyst Ratings for TherapeuticsMD.
Are investors shorting TherapeuticsMD?
TherapeuticsMD saw a increase in short interest during the month of April. As of April 30th, there was short interest totalling 57,526,791 shares, an increase of 1.7% from the April 13th total of 58,531,859 shares. Based on an average trading volume of 1,837,473 shares, the days-to-cover ratio is presently 31.3 days. Approximately 33.2% of the shares of the company are sold short.
Who are some of TherapeuticsMD's key competitors?
Some companies that are related to TherapeuticsMD include GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Hutchison China MediTech (HCM), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD) and Supernus Pharmaceuticals (SUPN).
Who are TherapeuticsMD's key executives?
TherapeuticsMD's management team includes the folowing people:
- Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 47)
- Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 56)
- Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 50)
- Mr. Daniel Alan Cartwright, CFO, Treasurer & Principal Accounting Officer (Age 60)
- Mr. Mitchell L. Krassan, Chief Strategy Officer and Exec. VP (Age 52)
Has TherapeuticsMD been receiving favorable news coverage?
News coverage about TXMD stock has been trending somewhat negative recently, according to Accern Sentiment Analysis. Accern ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TherapeuticsMD earned a daily sentiment score of -0.19 on Accern's scale. They also assigned press coverage about the company an impact score of 46.46 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are TherapeuticsMD's major shareholders?
TherapeuticsMD's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (9.08%), BlackRock Inc. (6.43%), Franklin Resources Inc. (4.88%), Stifel Financial Corp (0.86%), First Eagle Investment Management LLC (0.81%) and OppenheimerFunds Inc. (0.76%). View Institutional Ownership Trends for TherapeuticsMD.
Which major investors are selling TherapeuticsMD stock?
TXMD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Franklin Resources Inc., Guggenheim Capital LLC, Teacher Retirement System of Texas, Claraphi Advisory Network LLC and California State Teachers Retirement System. View Insider Buying and Selling for TherapeuticsMD.
Which major investors are buying TherapeuticsMD stock?
TXMD stock was bought by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC, DekaBank Deutsche Girozentrale, GSA Capital Partners LLP, Trellus Management Company LLC, Iridian Asset Management LLC CT, Cubist Systematic Strategies LLC, Schwab Charles Investment Management Inc. and Barclays PLC. View Insider Buying and Selling for TherapeuticsMD.
How do I buy shares of TherapeuticsMD?
Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TherapeuticsMD's stock price today?
One share of TXMD stock can currently be purchased for approximately $5.95.
How big of a company is TherapeuticsMD?
TherapeuticsMD has a market capitalization of $1.33 billion and generates $16.78 million in revenue each year. The company earns $-76,920,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. TherapeuticsMD employs 173 workers across the globe.
How can I contact TherapeuticsMD?
TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at [email protected]
MarketBeat Community Rating for TherapeuticsMD (TXMD)
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
TherapeuticsMD (NASDAQ:TXMD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for TherapeuticsMD in the last 12 months. Their average twelve-month price target is $14.8571, suggesting that the stock has a possible upside of 149.70%. The high price target for TXMD is $28.00 and the low price target for TXMD is $6.00. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.89 | 2.89 | 2.89 | 2.91 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $14.8571 | $14.50 | $14.50 | $14.7222 |
| Price Target Upside: | 149.70% upside | 184.31% upside | 189.42% upside | 130.01% upside |
TherapeuticsMD (NASDAQ:TXMD) Consensus Price Target History
TherapeuticsMD (NASDAQ:TXMD) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
TherapeuticsMD (NASDAQ:TXMD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
TherapeuticsMD (NASDAQ TXMD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 22.85%
Institutional Ownership Percentage: 72.70%
TherapeuticsMD (NASDAQ TXMD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/8/2017 | Tommy G Thompson | Director | Buy | 5,000 | $6.21 | $31,050.00 | 3,555 |  |
| 8/30/2017 | Tommy G Thompson | Director | Buy | 5,000 | $5.99 | $29,950.00 | 3,555 | |
| 3/11/2016 | Cooper C Collins | Director | Buy | 16,000 | $6.23 | $99,680.00 | 36,000 | |
| 8/25/2015 | Angus C Russell | Director | Buy | 13,500 | $5.98 | $80,730.00 | 48,500 | |
| 6/8/2015 | Mitchell Krassan | EVP | Sell | 30,000 | $8.18 | $245,400.00 | | |
| 5/12/2015 | Angus C Russell | Director | Buy | 35,000 | $6.15 | $215,250.00 | | |
| 5/11/2015 | Tommy G Thompson | Chairman | Buy | 6,000 | $6.09 | $36,540.00 | | |
| 5/8/2015 | J Martin Carroll | Director | Buy | 10,000 | $6.11 | $61,100.00 | | |
| 11/21/2014 | Daniel A Cartwright | CFO | Sell | 40,000 | $3.91 | $156,400.00 | | |
| 9/4/2014 | Tommy G Thompson | Director | Buy | 1,757 | $5.44 | $9,558.08 | | |
| 6/5/2014 | Cooper C Collins | Director | Buy | 20,000 | $3.84 | $76,800.00 | | |
| 5/9/2014 | Robert Lapenta, Jr. | Director | Buy | 5,000 | $3.66 | $18,300.00 | 10,000 | |
| 5/8/2014 | Tommy Thompson | Director | Buy | 14,000 | $3.57 | $49,980.00 | | |
| 3/26/2014 | Brian Bernick | Director | Sell | 421,268 | $6.70 | $2,822,495.60 | 297,000 | |
| 3/26/2014 | John C.K. Iv Milligan | Insider | Sell | 353,412 | $6.70 | $2,367,860.40 | 1,722,419 | |
| 3/26/2014 | Robert Finizio | CEO | Sell | 982,053 | $6.70 | $6,579,755.10 | 21,029,533 | |
| 3/10/2014 | Mitchell Krassan | EVP | Sell | 7,500 | $7.73 | $57,975.00 | | |
| 2/26/2014 | John C.K. Iv Milligan | President | Sell | 25,000 | $6.31 | $157,750.00 | 6,318,018 | |
| 2/21/2014 | Robert Finizio | CEO | Sell | 50,000 | $6.17 | $308,500.00 | 22,011,586 | |
| 2/12/2014 | Brian Bernick | Director | Sell | 31,250 | $6.16 | $192,500.00 | | |
| 1/30/2014 | John C.K. Iv Milligan | Insider | Sell | 25,000 | $6.16 | $154,000.00 | 6,343,018 | |
| 1/23/2014 | Robert G Finizio | CEO | Sell | 50,000 | $5.70 | $285,000.00 | | |
| 1/13/2014 | Mitchell Krassan | EVP | Sell | 7,500 | $5.73 | $42,975.00 | | |
| 1/8/2014 | Brian Bernick | Director | Sell | 31,250 | $5.13 | $160,312.50 | | |
| 8/26/2013 | Brian Bernick | Insider | Sell | 1,600,000 | $1.55 | $2,480,000.00 | | |
| 8/26/2013 | Jules A Musing | Director | Buy | 5,282 | $2.15 | $11,356.30 | | |
| 6/14/2013 | Cooper C Collins | Director | Sell | 2,631,579 | $1.75 | $4,605,263.25 | | |
(Data available from 1/1/2013 forward)
TherapeuticsMD (NASDAQ TXMD) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | $4.13 Million in Sales Expected for TherapeuticsMD Inc (TXMD) This Quarter
www.americanbankingnews.com - May 21 at 4:22 AM |
| Brokerages Anticipate TherapeuticsMD Inc (TXMD) to Announce -$0.12 Earnings Per Share
www.americanbankingnews.com - May 19 at 9:25 AM |
 | TherapeuticsMD Announces Investor and Analyst Day on June 4
finance.yahoo.com - May 16 at 5:40 PM |
 | TikaMobile Selected by TherapeuticsMD as Business Intelligence Platform Provider
globenewswire.com - May 16 at 8:20 AM |
| TherapeuticsMD Sees Unusually Large Options Volume (TXMD)
www.americanbankingnews.com - May 16 at 6:46 AM |
| TherapeuticsMD (TXMD) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 9 at 6:51 PM |
| TherapeuticsMD (TXMD) Lifted to "Buy" at ValuEngine
www.americanbankingnews.com - May 8 at 3:29 PM |
| FY2020 EPS Estimates for TherapeuticsMD Inc Lowered by Oppenheimer (TXMD)
www.americanbankingnews.com - May 7 at 5:17 AM |
 | TherapeuticsMD's (TXMD) CEO Robert Finizio on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 5 at 8:28 AM |
| Oppenheimer Reiterates $10.00 Price Target for TherapeuticsMD (TXMD)
www.americanbankingnews.com - May 4 at 10:31 PM |
| Edited Transcript of TXMD earnings conference call or presentation 3-May-18 8:30pm GMT
finance.yahoo.com - May 4 at 5:32 PM |
| TherapeuticsMD (TXMD) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - May 4 at 3:32 PM |
| TherapeuticsMD: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 8:19 AM |
 | BRIEF-Therapeutics MD Reports Loss Per Share Of $0.11
www.reuters.com - May 3 at 5:23 PM |
| TherapeuticsMD Announces First Quarter 2018 Financial Results
finance.yahoo.com - May 3 at 5:23 PM |
| $4.10 Million in Sales Expected for TherapeuticsMD Inc (TXMD) This Quarter
www.americanbankingnews.com - May 3 at 2:30 AM |
| TherapeuticsMD (TXMD) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - May 2 at 3:48 PM |
| Zacks: Brokerages Anticipate TherapeuticsMD Inc (TXMD) to Post -$0.10 EPS
www.americanbankingnews.com - May 1 at 7:14 PM |
| TherapeuticsMD to Host First Quarter Financial Results Conference Call and Webcast on May 3
finance.yahoo.com - May 1 at 5:17 PM |
 | Drug Makers Stocks' Research Reports Released on Sanofi, Shire, TherapeuticsMD, and Zogenix
www.prnewswire.com - April 26 at 8:18 AM |
| TherapeuticsMD (TXMD) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 25 at 2:58 PM |
| TherapeuticsMD (TXMD) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 18 at 2:28 PM |
| Analysts Anticipate TherapeuticsMD Inc (TXMD) Will Post Quarterly Sales of $4.10 Million
www.americanbankingnews.com - April 16 at 2:19 AM |
| TherapeuticsMD Inc (TXMD) Expected to Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - April 14 at 7:18 PM |
| BRIEF-TherapeuticsMD Enters Into Negotiations With US FDA For TX-004HR
www.reuters.com - April 13 at 8:20 AM |
| TherapeuticsMD (TXMD) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - April 11 at 1:23 PM |
| TherapeuticsMD Enters Into Label Negotiations for TX-004HR
finance.yahoo.com - April 11 at 8:32 AM |
| TherapeuticsMD (TXMD) PT Set at $10.00 by Deutsche Bank
www.americanbankingnews.com - April 9 at 10:52 PM |
| TherapeuticsMD (TXMD) PT Set at $10.00 by Oppenheimer
www.americanbankingnews.com - April 6 at 10:22 PM |
| TherapeuticsMD (TXMD) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 5 at 6:21 PM |
| TherapeuticsMD (TXMD) Upgraded at ValuEngine
www.americanbankingnews.com - April 2 at 10:52 PM |
| TherapeuticsMD Announces Expansion of Board of Directors
finance.yahoo.com - April 2 at 8:41 AM |
| TherapeuticsMD (TXMD) Upgraded to Sell by BidaskClub
www.americanbankingnews.com - March 30 at 10:02 PM |
| TherapeuticsMD Inc (TXMD) Expected to Announce Quarterly Sales of $4.21 Million
www.americanbankingnews.com - March 30 at 1:52 AM |
| TherapeuticsMD (TXMD) Receives Buy Rating from Oppenheimer
www.americanbankingnews.com - March 21 at 7:48 PM |
 | Quotidian Technical Highlights on Selected Drug Makers Stocks -- Sanofi, Shire, TherapeuticsMD, and Zogenix
www.bizjournals.com - March 19 at 5:17 PM |
| TherapeuticsMD, New PipelineNDA Development, Analysts Target and PDUFA Date
finance.yahoo.com - March 19 at 8:24 AM |
| TherapeuticsMD Inc (TXMD) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 18 at 3:42 AM |
| Brokerages Expect TherapeuticsMD Inc (TXMD) to Post -$0.09 EPS
www.americanbankingnews.com - March 11 at 2:12 PM |
| TherapeuticsMD Inc (TXMD) Short Interest Update
www.americanbankingnews.com - March 11 at 1:58 AM |
 | The 5 Most Shorted Nasdaq Stocks
www.msn.com - March 10 at 6:23 PM |
| TherapeuticsMD (TXMD) Given "Buy" Rating at Noble Financial
www.americanbankingnews.com - March 10 at 5:09 PM |
 | Therapeutics Wins FDA Nod, Stocks Don't Budge
www.baystreet.ca - March 9 at 6:49 PM |
| TherapeuticsMD (TXMD) Given a $10.00 Price Target at Oppenheimer
www.americanbankingnews.com - March 9 at 2:44 PM |
 | TherapeuticsMD (TXMD) FDA Accepts TX-001HR NDA; 10/28/18 ... - StreetInsider.com
www.streetinsider.com - March 9 at 8:21 AM |
| Today’s Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and TherapeuticsMD
finance.yahoo.com - March 9 at 8:21 AM |
| BRIEF-TherapeuticsMD Announces FDA Acceptance Of New Drug Application For Tx-001Hr
www.reuters.com - March 8 at 6:41 PM |
| TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for TX-001HR
finance.yahoo.com - March 8 at 6:41 PM |
 | TherapeuticsMD to Present at Two Upcoming Investor Conferences ... - Business Wire (press release)
www.businesswire.com - March 7 at 8:19 AM |
 | Commit To Purchase TherapeuticsMD At $3, Earn 17.2% Annualized Using Options - Nasdaq
www.nasdaq.com - March 7 at 8:19 AM |
TherapeuticsMD (NASDAQ:TXMD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
TherapeuticsMD (NASDAQ:TXMD) Income Statement, Balance Sheet and Cash Flow Statement
TherapeuticsMD (NASDAQ TXMD) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
